^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JNJ-8543

i
Other names: JNJ-8543, JNJ-80948543, JNJ80948543, JNJ8543, JNJ 80948543, JNJ 8543
Associations
Company:
J&J
Drug class:
CD20 inhibitor, CD3 agonist, T-cell stimulant, CD79B inhibitor
Related drugs:
Associations
25d
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
4ms
Trial primary completion date • Trispecific
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543
11ms
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
Enrollment open • Trial completion date • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
12ms
Trial completion date • Trispecific
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543
1year
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
over1year
Trial completion date • Trispecific
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543
over1year
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2024
Trial completion date • Trial primary completion date • Trispecific
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543
2years
Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma (ASH 2022)
Taken together, JNJ-80948543 is a potential first-in-class trispecific antibody for the treatment of B‑NHL malignancies with high unmet medical needs. A Phase I dose-escalation study of JNJ-80948543 in patients with relapsed/refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (CLL) will be initiated.
IO biomarker
|
CD79B (CD79b Molecule)
|
JNJ-8543
over2years
Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543
over2years
New P1 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
JNJ-8543